Skip to main
IRON
IRON logo

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc has reinforced a positive outlook due to its enhanced probability of success for the FDA approval of bitopertin, which has been increased to 100%, indicating strong confidence in the drug's market potential. The company's revenue projections for upcoming years show a significant upward trajectory, with estimated sales reaching $35 million in 2026, $190 million in 2027, and escalating to $615 million by 2029, driven in part by favorable assessments for its other leading candidates, DISC-0974 and DISC-3405. Additionally, the receipt of a Commissioner’s National Priority Voucher has expedited the review process for bitopertin, further enhancing the potential for timely market entry and revenue generation.

Bears say

Disc Medicine Inc. faces significant financial pressures due to potential pricing erosion from competition, including generics, and significant risks associated with its intellectual property, which may impede future revenue generation and valuation. Additionally, the company has limited cash reserves, necessitating future capital raises that may prove challenging in fluctuating market conditions, thereby impacting its operational viability and commercialization efforts of its pipeline. Furthermore, the clinical trial landscape presents inherent risks, including the possibility that their lead candidate, bitopertin, may fail to demonstrate significant therapeutic benefits, leading to regulatory hurdles and affecting investor confidence in the company’s financial and operational prospects.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.